This second tranche of $15 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.
Guy Macdonald, president and CEO of Tetraphase, said: “Since our inception, we have made significant progress, applying our unique technology to the development of several novel and potent antibiotic drug candidates. We are very pleased that our investors share our enthusiasm for and confidence in our programs.”